Moderna shares rise to close out a week of wild swings. Crypto stocks also extend their recent rally.
After demand for its COVID-19 shots plummeted, its new treatment for melanoma has reversed the Mass. company’s fortunes.
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the ...
Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...
MEXC, a pioneer in 0-fee digital asset trading, has listed the MRNAON/USDT trading pair on Spot, giving users a new ...
Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of ...
Moderna stock soared 177% after a major cancer vaccine breakthrough. See Wall Street’s latest MRNA price targets and whether ...
Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its ...
Investor's Business Daily on MSN
Moderna stock is just the start: Why AI-focused money might flow into biotech
Moderna stock could catch the eye of investors looking for the next big AI play, Revere Asset Management's Don Vandenbord says.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results